How does eye cancer treatment affect daily life? new study aims to find out
NCT ID NCT07421739
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tracks how choroidal melanoma and its treatment affect patients' quality of life. It involves 15 people already in a larger Phase 3 trial. Participants fill out questionnaires about their well-being over two years. No new drugs or procedures are tested here.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 15 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Nov 2025
- Expected to finish
-
Aug 2028
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Participating in Aura's Phase 3 CoMpass trial.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Have enrolled in the Aura-sponsored clinical trial AU-011-301. * Access to a connected device (i.e., smartphone, laptop, or tablet) Exclusion Criteria: * None
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Choroidal melanoma are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The study's own enquiry address
This study publishes an address for enquiries. See it below .
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Eye Research Australia
RECRUITINGEast Melbourne, Victoria, 3002, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Hepatic arterial infusion of autologous tumor infiltrating lymphocytes preconditioned with percutaneous hepatic perfusion with melphalan in patients with melanoma and liver metastases
- Can a pill combo keep uveal melanoma from coming back?
- Can tracking a rare eye cancer pave the way for new treatments?
- Can a new drug tame advanced solid tumors?
- Can a single eye injection shrink melanoma and save sight?
- Supercharged immune cells take aim at childhood cancers